46 articles for M Tanaka
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
18
Discovery of 4-chloro-2-(2,4-dichloro-6-methylphenoxy)-1-methyl-7-(pentan-3-yl)-1H-benzimidazole, a novel CRF

Takeda Pharmaceutical
32
Discovery of ONO-7300243 from a Novel Class of Lysophosphatidic Acid Receptor 1 Antagonists: From Hit to Lead.

Ono Pharmaceutical
25
Design and Synthesis of Benzimidazoles As Novel Corticotropin-Releasing Factor 1 Receptor Antagonists.

Takeda Pharmaceutical
1
A phenotypic drug discovery study on thienodiazepine derivatives as inhibitors of T cell proliferation induced by CD28 co-stimulation leads to the discovery of a first bromodomain inhibitor.

Mitsubishi Tanabe Pharma
45
Discovery of 6-phenylpyrimido[4,5-b][1,4]oxazines as potent and selective acyl CoA:diacylglycerol acyltransferase 1 (DGAT1) inhibitors with in vivo efficacy in rodents.

Amgen
31
A novel tamoxifen derivative, ridaifen-F, is a nonpeptidic small-molecule proteasome inhibitor.

Institute of Bio-Science and Technology
28
Potent proteasome inhibitors derived from the unnatural cis-cyclopropane isomer of Belactosin A: synthesis, biological activity, and mode of action.

Hokkaido University
20
Synthesis and biological evaluation of novel tryptoline derivatives as indoleamine 2,3-dioxygenase (IDO) inhibitors.

Toho University
26
Synthesis of anilino-monoindolylmaleimides as potent and selective PKCbeta inhibitors.

Central Pharmaceutical Research Institute
8
Synthesis and inhibitory effects of bivalent sialyl lewis X analogs at preventing cell adhesion

TBA
24
Design and synthesis of new prostaglandin D2 receptor antagonists.

Minase Research Institute
47
Discovery of (1S,2R,3R)-2,3-dimethyl-2-phenyl-1-sulfamidocyclopropanecarboxylates: novel and highly selective aggrecanase inhibitors.

Central Pharmaceutical Research Institute
3
Synthesis and galectin-binding activities of mercaptododecyl glycosides containing a terminalß-galactosyl group.

National Institute of Advanced Industrial Science and Technology (Aist)
3
Ipomotaosides A-D, resin glycosides from the aerial parts of Ipomoea batatas and their inhibitory activity against COX-1 and COX-2.

Tokushima Bunri University
51
Discovery of pyrrolopyridazines as novel DGAT1 inhibitors.

Amgen
23
Discovery of novel N-acylsulfonamide analogs as potent and selective EP3 receptor antagonists.

Minase Research Institute
16
3-(2-Aminocarbonylphenyl)propanoic acid analogs as potent and selective EP3 receptor antagonists. Part 1: discovery and exploration of the carboxyamide side chain.

Minase Research Institute
51
3-(2-Aminocarbonylphenyl)propanoic acid analogs as potent and selective EP3 receptor antagonists. part 2: optimization of the side chains to improve in vitro and in vivo potencies.

Minase Research Institute
3
Alteration of Na
+ permeability in human erythrocytes as studied by
23Na-NMR and inhibition of the kidney Na
+,K
+-ATPase activities with saponins: Interaction of
Gleditsia saponins with human erythrocyte membranes

TBA
16
Discovery of ONO-TR-772 (VU6018042): A Highly Selective and CNS Penetrant TREK Inhibitor in Vivo Tool Compound.

Ono Pharmaceutical Co., Ltd
30
Development of novel BACE1 inhibitors with a hydroxyproline-derived N-amidinopyrrolidine scaffold.

Kyoto Pharmaceutical University
23
Discovery of 5-phenyl-3-ureidothiophene-2-carboxamides as protective agents for ALS patient iPSC-derived motor neurons.

Toray Industries
21
New class of corticotropin-releasing factor (CRF) antagonists: small peptides having high binding affinity for CRF receptor.

Central Pharmaceutical Research Institute
17
Fluorescent H

University of Regensburg
9
2-Acylimino-3H-thiazoline derivatives: a novel template for platelet GPIIb/IIIa receptor antagonists.

Taisho Pharmaceutical
2
The C4 hydroxyl group of phorbol esters is not necessary for protein kinase C binding.

Kyoto University
20
Discovery of a 7-arylaminobenzimidazole series as novel CRF1 receptor antagonists.

Takeda Pharmaceutical
27
[

University of Regensburg
40
Identification of a Selective, Non-Prostanoid EP2 Receptor Agonist for the Treatment of Glaucoma: Omidenepag and its Prodrug Omidenepag Isopropyl.

Ube Industries
67
Orally active, nonpeptide vasopressin V2 receptor antagonists: a novel series of 1-[4-(benzoylamino)benzoyl]-2,3,4,5-tetrahydro-1H-benzazepines and related compounds.

Otsuka Pharmaceutical
52
Discovery of potent liver-selective stearoyl-CoA desaturase-1 (SCD1) inhibitors, thiazole-4-acetic acid derivatives, for the treatment of diabetes, hepatic steatosis, and obesity.

Japan Tobacco
10
Design and synthesis of estrogen receptor ligands with a 4-heterocycle-4-phenylheptane skeleton.

Nagasaki University
23
Discovery of 1,2,3,4-tetrahydropyrimido[1,2-a]benzimidazoles as novel class of corticotropin releasing factor 1 receptor antagonists.

Takeda Pharmaceutical
12
Synthesis and beta-lactamase inhibitory properties of 2 beta-[(1,2,3-triazol-1-yl)methyl]-2 alpha-methylpenam-3 alpha-carboxylic acid 1,1-dioxide and related triazolyl derivatives.

TBA
17
Ridaifen-F conjugated with cell-penetrating peptides inhibits intracellular proteasome activities and induces drug-resistant cell death.

Nagahama Institute of Bio-Science and Technology
19
Discovery of a Slow Tight Binding LPA1 Antagonist (ONO-0300302) for the Treatment of Benign Prostatic Hyperplasia.

Ono Pharmaceutical
3
Adenosine analogs as methyltransferase inhibitors for treating cancer

Memorial Sloan-Kettering Cancer Center
73
OXOPYRROLIDINE UREA FPR2 AGONISTS

Bristol Myers Squibb
144
AMINO ACID COMPOUNDS AND METHODS OF USE

Pliant Therapeutics
601
TYK2 inhibitors and uses thereof

Nimbus Lakshmi
10
Chemical compounds

Glaxosmithkline Intellectual Property (No. 2)
34
Triazolopyridines

Hoffmann-La Roche
6
Catecholamine prodrugs for use in the treatment of Parkinson's disease

H. Lundbeck
23
Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]OXAZEPINES and methods for treating viral infections

Gilead Sciences
10
INTERACTION OF AROMATIC COMPOUNDS WITH ALPHA-CHYMOTRYPSIN. II. COMBINATION OF THE ISOMERIC INDOLE CARBOXAMIDES AND CARBOXYLATE IONS WITH THE ACTIVE SITE.

California Institute of Technology
13
Investigation of the effect of varying the 4-anilino and 7-alkoxy groups of 3-quinolinecarbonitriles on the inhibition of Src kinase activity.

Wyeth Research